Wanwisa DejnirattisaiWiyada WongwiwatSunpetchuda SupasaXiaokang ZhangXinghong DaiAlexander RouvinskyAmonrat JumnainsongCarolyn EdwardsNguyen Than Ha QuyenThaneeya DuangchindaJonathan M. GrimesWen Yang TsaiChih Yun LaiWei Kung WangPrida MalasitJeremy FarrarCameron P. SimmonsZ. Hong ZhouFelix A. ReyJuthathip MongkolsapayaGavin R. ScreatonImperial College LondonMahidol UniversityInstitut Pasteur, ParisCNRS Centre National de la Recherche ScientifiqueUniversity of California, Los AngelesKhon Kaen UniversityUCLThailand National Center for Genetic Engineering and BiotechnologyWellcome Trust Centre for Human GeneticsScience DivisionUniversity of Hawaii at Manoa John A. Burns School of MedicineUniversity of Melbourne2018-11-232018-11-232015-01-01Nature Immunology. Vol.16, No.2 (2015), 170-17715292916152929082-s2.0-84922947115https://repository.li.mahidol.ac.th/handle/20.500.14594/36166© 2015 Nature America, Inc. Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.Mahidol UniversityImmunology and MicrobiologyArticleSCOPUS10.1038/ni.3058